Premier Alternatives

Dxcover

Glasgow, United Kingdom · Founded 2016 · Privately Held (backing)

Developer of a liquid biopsy-based cancer diagnostics platform designed for the early detection of multiple cancer types. Dxcover is based in Glasgow, United Kingdom and was founded in 2016. Its last reported valuation was $37.8 million in Jan 2025. It has raised $21.8 million.

Last reported valuation
$37.8M
Oct 2026
Priced at
—
Total raised
$21.8M
Last round
—

Dxcover key facts

as of Oct 2026
  • Developer of a liquid biopsy-based cancer diagnostics platform designed for the early detection of multiple cancer types.
  • Dxcover is valued at approximately $37.8M as of Oct 2026 (last reported valuation).
  • It has raised $21.8M; the latest was Accelerator/Incubator ($6.2M) in Mar 2026.
  • Notable investors include Innovate UK, European Innovation Council, Tech Nation Group, Scottish Enterprise, Mercia Ventures — 24 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$37.8M

Dxcover's last reported valuation, Jan 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Dxcover with a free account
  • ·The complete investor list: 24 names
  • ·Watch Dxcover: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Dxcover funding rounds

No rounds on record

No funding rounds for Dxcover are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Dxcover valuation

Dxcover's last reported valuation was $37.8 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.

Dxcover investors

24 investors are on record for Dxcover, including Innovate UK, European Innovation Council, Tech Nation Group and Scottish Enterprise.

About Dxcover

Developer of a liquid biopsy-based cancer diagnostics platform designed for the early detection of multiple cancer types. The company's platform combines infrared spectroscopy with multi-omic data analysis and machine learning algorithms to analyze blood samples, detect spectral signatures associated with disease, generate rapid diagnostic outputs without complex sample preparation, support high-throughput screening and triage of high-risk populations, integrate clinical data for improved predictive accuracy, and enable scalable deployment across healthcare settings, enabling clinicians, healthcare providers, and research institutions to identify cancers at earlier stages and improve diagnostic efficiency and patient outcomes.

Sector
Healthcare
HQ
Glasgow, United Kingdom
Founded
2016
Employees
31
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.